The FDA will continue to take aggressive enforcement action to safeguard the public from harmful drug products illegally marketed as treatments for which they have not been studied or approved, said Melinda Plaisier, the FDAs associate commissioner for regulatory affairs.
Date: Sep 08, 2016
Category: Health
Source: Google
Kratom to join heroin, LSD on Schedule I drug list
import alert that allowed US Customs agents to detain kratom without a physical examination. "We have identified kratom as a botanical substance that could pose a risk to public health and have the potential for abuse," said Melinda Plaisier, the FDA's associate commissioner for regulatory affairs.
Date: Aug 31, 2016
Category: Health
Source: Google
Judge orders injunction against New Jersey compounding pharmacy
The Med Prep decree "shows that the FDA will take aggressive enforcement actions to ensure the safety of its drugs," FDA acting associate commissioner for regulatory affairs Melinda Plaisier said in a statement.